Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

191
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
191
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

324
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
324
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

232
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
232
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

422
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
422
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

315
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
315
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

169
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of missing data approaches for linear regression with missing not at random outcome and predictors.

Statistical methods in medical research·2026
Same author

Sample Size Calculation for the ROCI Design.

Statistics in medicine·2026
Same author

CRT-Estimands Framework: consensus based extension of the ICH E9(R1) addendum for cluster randomised trials.

BMJ (Clinical research ed.)·2026
Same author

How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study.

BMC medical research methodology·2026
Same author

Bayesian analysis in confirmatory clinical trials: A narrative review and discussion of current practice.

Clinical trials (London, England)·2026
Same author

PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort study.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Sep 4, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.4K

Rethinking intercurrent events in defining estimands for tuberculosis trials.

Tra My Pham1, Conor D Tweed1, James R Carpenter1,2

  • 1MRC Clinical Trials Unit at UCL, London, UK.

Clinical Trials (London, England)
|July 19, 2022
PubMed
Summary

This study clarifies how to define outcomes in tuberculosis trials by addressing post-randomisation events. Improved definitions enhance the interpretation and comparison of treatment effects in clinical research.

Keywords:
Tuberculosisestimandintention to treatintercurrent eventsper protocol

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Related Experiment Videos

Last Updated: Sep 4, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.4K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Area of Science:

  • Clinical Trials Methodology
  • Infectious Disease Epidemiology
  • Statistical Analysis in Medicine

Background:

  • Tuberculosis (TB) is a major global infectious disease killer.
  • Inconsistent outcome definitions and handling of post-randomisation events in TB trials hinder interpretation and comparison.
  • The ICH E9(R1) addendum provides a framework for defining estimands.

Purpose of the Study:

  • To identify key decisions and considerations for defining outcomes in TB treatment trials using the estimand framework.
  • To address the handling of intercurrent events (ICEs) and loss to follow-up in TB clinical trials.
  • To improve the clarity and comparability of treatment effects estimated in TB research.

Main Methods:

  • Applied the estimand framework to analyze handling of post-randomisation events in TB trials.
  • Considered common ICEs: treatment changes, poor adherence, re-infection, and death.
  • Utilized data from two completed Phase III TB trials (REMoxTB and STREAM Stage 1) as examples.

Main Results:

  • Proposed strategies for handling ICEs: quantify harms of regimen changes, develop methods for programmatic relevance in adherence analysis, differentiate re-infection strategies, separate death causes, and distinguish loss to follow-up from treatment completion.
  • Treatment changes should be quantified for patient harm, not automatically deemed unfavorable.
  • Loss to follow-up should be analyzed separately from intercurrent events like treatment discontinuation.

Conclusions:

  • The estimand framework clarifies issues but necessitates improved outcome definitions in TB trials.
  • Future TB trialists must carefully consider proposed points for defining outcomes.
  • Enhanced outcome definitions will improve the reliability and interpretability of TB treatment trial results.